title: Kidney disease in RA patients: prevalence and implication on RA-related drugs management: the MATRIX study.
abstract: OBJECTIVE
  The prevalence of kidney disease (KD) indicators together with the profile of RA drugs prescribed in RA patients was investigated in the MATRIX study (MeThotreXate And Renal Insufficiency).
  
  
  METHODS
  Renal function (RF) was assessed using Cockcroft-Gault (CG) and abbreviated Modification of Diet in Renal Disease (aMDRD) study formulae.
  
  
  RESULTS
  Serum creatinine (SCr) was normal in 81.4% of the 129 patients included. According to the National Kidney Foundation (NKF) classification, the distribution by stage of KD was, using the aMDRD and CG formulae, as follows: stage 1: 11.3% and 11.4%; stage 2: 20.0% and 20.3%; stage 3: 15.0% and 24.1%; stage 4: 0% and 1.3%; stage 5: 0%. Proteinuria, haematuria and leucocyturia were observed in 16%, 17% and 20% of the patients, respectively. Using the aMDRD and CG formulae, 36% and 38% of the prescriptions made in patients with glomerular filtration rate (GFR) <60 ml/min required a dosage adjustment. Among the patients with GFR <60 ml/min, 83-90% received at least one drug that required a dosage adjustment and 67-70% received at least one drug that was potentially nephrotoxic, according to aMDRD or CG formulae, respectively. Five (50%) and 8 (47%) patients did not have appropriate MTX dosage adjustment according to their stage of KD with aMDRD or CG formulae, respectively.
  
  
  CONCLUSIONS
  Systematic estimation of RF with CG or aMDRD formulae and urine dipstick are necessary in RA patients. In patients with KD at high risk for drug toxicity, dosage should be adapted to RF.
authors.affiliation: Department of Nephrology, Hôpital Pitié-Salpêtrière, 47-83, boulevard de l'hôpital, 75013 Paris, France. svetlana.karie@psl.aphp.fr
authors.forename: S
authors.initials: S
authors.lastname: Karie
authors.forename: F
authors.initials: F
authors.lastname: Gandjbakhch
authors.forename: N
authors.initials: N
authors.lastname: Janus
authors.forename: V
authors.initials: V
authors.lastname: Launay-Vacher
authors.forename: S
authors.initials: S
authors.lastname: Rozenberg
authors.forename: C U
authors.initials: CU
authors.lastname: Mai Ba
authors.forename: P
authors.initials: P
authors.lastname: Bourgeois
authors.forename: G
authors.initials: G
authors.lastname: Deray
mesh_terms: D000328:Adult; D017677:Age Distribution; D000368:Aged; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology*; D015897:Comorbidity; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006801:Humans; D007674:Kidney Diseases / Q000453:epidemiology* / Q000209:etiology / Q000503:physiopathology; D007677:Kidney Function Tests; D008297:Male; D008727:Methotrexate / Q000009:adverse effects* / Q000627:therapeutic use; D008875:Middle Aged; D015995:Prevalence; D011446:Prospective Studies; D011507:Proteinuria / Q000175:diagnosis; D018570:Risk Assessment; D017678:Sex Distribution; D016482:Urinalysis
chemical_list: D018501:Antirheumatic Agents; D008727:Methotrexate